Laxdale Ltd Report issue

Contributed to NME For profit Phase 3
Founded: Stirling United Kingdom (1997)
Status: Left NME R&D (2011)

Organization Overview

First Clinical Trial
2001
NCT00419146
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2001

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

icosapent ethyl (vascepa) (1 trial)

vitamin c (1 trial)

vitamin e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 3)

Mental Disorders (Phase 3)

Psychotic Disorders (Phase 3)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3